Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib + Atezolizumab in FGFR+ Urothelial Carcinoma
NCT03473756Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2018
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of rogaratinib in urothelial carcinoma (UC), sponsored by Bayer. Primary endpoints: Number of Participants With Dose-limiting Toxicities up to 21 days, Number of Participants With Treatment-emergent Adverse Events and 2 more. Started May 2018; status: completed.
02
Drugs
rogaratinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03473756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473756.